CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Multiple Immune Related Adverse Events in a Patient with Metastatic Melanoma
Provisionally accepted
- The University of New Mexico Comprehensive Cancer Center, Albuquerque, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune related adverse events (irAEs) are a well-recognized potential complication of immunotherapy treatment. Immunotherapy works at the level of T-cells and tumors to blunt checkpoints that normally suppress overactivation of the immune response. While this leads to a therapeutic benefit in many cases, the dysregulated immune system can also attack healthy parts of the body, leading to toxicity. For stage IV melanoma, combination checkpoint inhibition with multiple drugs agents is the preferred frontline treatment, however, this can increase the risk of irAEs. This case describes a person treated with the Lymphocyte-activation gene 3 (LAG-3) inhibitor relatlimab and the Programmed cell death protein 1 (PD-1) inhibitor nivolumab for stage IV melanoma who subsequently developed four distinct and significant toxicities.
Keywords: Immune related adverse events, Melanoma, Nivolumab, Relatlimab, side effect
Received: 01 Aug 2025; Accepted: 25 Nov 2025.
Copyright: © 2025 Varada, DO, Yang and Savage, MD, PhD. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Neilmegh Lakshman Varada, DO
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.